Media headlines about ObsEva SA (NASDAQ:OBSV) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ObsEva SA earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.8356475827974 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Royal Bank Of Canada Begins Coverage on ObsEva SA (OBSV) (americanbankingnews.com)
- ObsEva SA (OBSV) Given Consensus Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- ObsEva SA – ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting (romandie.com)
- ObsEva Announces Presentation Related To Its PGF2alpha Receptor Antagonist At Annual Meeting (biospace.com)
A number of equities research analysts recently commented on OBSV shares. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of ObsEva SA in a report on Friday, September 8th. Zacks Investment Research lowered shares of ObsEva SA from a “hold” rating to a “sell” rating in a report on Saturday, August 19th. Royal Bank Of Canada started coverage on shares of ObsEva SA in a report on Thursday, September 14th. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, Leerink Swann restated an “outperform” rating and set a $18.00 price objective on shares of ObsEva SA in a report on Wednesday, August 16th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.00.
Shares of ObsEva SA (NASDAQ:OBSV) opened at 7.14 on Tuesday. The company’s 50 day moving average is $6.99 and its 200-day moving average is $7.87. The firm’s market capitalization is $203.46 million. ObsEva SA has a one year low of $6.77 and a one year high of $14.18.
ObsEva SA (NASDAQ:OBSV) last issued its earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same period last year, the company earned ($0.30) EPS. Equities analysts expect that ObsEva SA will post ($2.38) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact ObsEva SA (OBSV) Stock Price” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/09/19/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-obseva-sa-obsv-stock-price.html.
ObsEva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.